GlaxoSmithKline could reportedly be targeted by Roche, Johnson & Johnson
Pharmaceuticals giant GlaxoSmithKline could reportedly become the latest takeover target in the industry.
FTSE 100
8,177.15
16:39 01/11/24
n/a
n/a
FTSE 350
4,508.38
17:14 01/11/24
n/a
n/a
FTSE All-Share
4,465.61
16:54 01/11/24
n/a
n/a
GSK
1,419.50p
16:47 01/11/24
1.94%
27.00p
Pharmaceuticals & Biotechnology
21,001.36
17:14 01/11/24
0.32%
66.51
According to the Daily Mail, market participants are speculating that the company may face an approach from Switzerland’s Roche or US company Johnson & Johnson at about 1900p per share.
Such a move would value GSK at more than £92bn.
Speaking over the weekend to Sharecast, Alistair McCaig, senior market analyst at IG, highlighted UK-listed pharmaceuticals as one of his favourites given the continuing need for American outfits to beef-up their product pipelines after a dearth of investment in recent years.